Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-09 11:16 am Purchase | 2022-12-30 | 13G | Denali Therapeutics Inc. DNLI | The Vanguard Group | 9,947,098 7.320% | 1,785,568 (+21.88%) | Filing History |
| 2023-02-09 08:14 am Sale | 2023-02-09 | 13G | Denali Therapeutics Inc. DNLI | FMR LLC | 5,854,035 4.310% | -737,998 (-11.20%) | Filing History |
| 2023-01-31 5:52 pm Purchase | 2022-12-31 | 13G | Denali Therapeutics Inc. DNLI | BlackRock Inc. BLK | 9,321,429 6.900% | 1,210,607 (+14.93%) | Filing History |
| 2023-01-20 10:05 am Purchase | 2022-12-30 | 13G | Denali Therapeutics Inc. DNLI | BAILLIE GIFFORD & CO | 15,119,474 11.130% | 63,093 (+0.42%) | Filing History |
| 2022-02-14 2:37 pm Sale | 2021-12-31 | 13G | Denali Therapeutics Inc. DNLI | BRATTON DOUGLAS K | 7,845,189 6.400% | -4,503,595 (-36.47%) | Filing History |
| 2022-02-14 2:34 pm Sale | 2021-12-31 | 13G | Denali Therapeutics Inc. DNLI | T. Rowe Price Associates, Inc. | 4,635,433 3.700% | -1,829,393 (-28.30%) | Filing History |
| 2022-02-09 3:43 pm Purchase | 2021-12-31 | 13G | Denali Therapeutics Inc. DNLI | The Vanguard Group | 8,161,530 6.680% | 236,473 (+2.98%) | Filing History |
| 2022-02-09 09:11 am Purchase | 2022-02-08 | 13G | Denali Therapeutics Inc. DNLI | FMR LLC | 6,592,033 5.397% | 424,096 (+6.88%) | Filing History |
| 2022-02-08 3:04 pm Sale | 2021-12-31 | 13G | Denali Therapeutics Inc. DNLI | ARCH Venture Fund VIII L.P. | 0 0.000% | -10,735,948 (Position Closed) | Filing History |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Denali Therapeutics Inc. DNLI | BlackRock Inc. BLK | 8,110,822 6.600% | 1,734,744 (+27.21%) | Filing History |
| 2022-01-18 11:50 am Purchase | 2021-12-31 | 13G | Denali Therapeutics Inc. DNLI | BAILLIE GIFFORD & CO | 15,056,381 12.330% | 2,866,125 (+23.51%) | Filing History |
| 2021-02-16 5:08 pm Sale | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | Flagship Ventures Fund V, L.P. | 2,730,263 2.200% | -5,250,000 (-65.79%) | Filing History |
| 2021-02-16 12:24 pm Purchase | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | T. Rowe Price Associates, Inc. | 6,464,826 5.300% | 6,464,826 (New Position) | Filing History |
| 2021-02-12 4:19 pm Sale | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | BRATTON DOUGLAS K | 12,348,784 10.300% | -8,066,751 (-39.51%) | Filing History |
| 2021-02-10 10:46 am Purchase | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | The Vanguard Group | 7,925,057 6.610% | 1,717,515 (+27.67%) | Filing History |
| 2021-02-08 10:19 am Purchase | 2021-02-05 | 13G | Denali Therapeutics Inc. DNLI | FMR LLC | 6,167,937 5.143% | 379,133 (+6.55%) | Filing History |
| 2021-02-02 5:04 pm Purchase | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | ARCH Venture Fund VIII L.P. | 10,735,948 9.000% | 37,339 (+0.35%) | Filing History |
| 2021-02-02 2:56 pm Purchase | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | BlackRock Inc. BLK | 6,376,078 5.300% | 1,348,764 (+26.83%) | Filing History |
| 2021-01-12 09:24 am Purchase | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | BAILLIE GIFFORD & CO | 12,190,256 10.170% | 4,600,009 (+60.60%) | Filing History |
| 2020-09-28 4:11 pm Purchase | 2020-09-22 | 13G | Denali Therapeutics Inc. DNLI | BIOGEN INC. BIIB | 13,310,243 11.160% | 13,310,243 (New Position) | Filing History |